Acute Myeloid Leukemia T 8 21 Q22 Q22 1 Cn372149
AML with a translocation between chromosomes 8 and 21. Generally considered to have a more favorable outlook, commonly affecting younger adults.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fever
(hematologic)Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Night sweats
(hematologic)Weight loss
(hematologic)Joint pain
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
High-Dose Cytarabine Consolidation
Intensive post-remission chemotherapy with high-dose cytarabine to eliminate remaining leukemia cells. This translocation typically confers a favorable prognosis with standard chemotherapy approaches.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Additional treatment options
Autologous Stem Cell Transplant
Collection and reinfusion of patient's own stem cells after high-dose chemotherapy. Considered for standard-risk patients achieving complete remission without a suitable donor.
procedureGemtuzumab Ozogamicin Addition
Addition of this anti-CD33 antibody-drug conjugate to standard chemotherapy for CD33-positive AML. Shows particular efficacy in core-binding factor leukemias like t(8;21).
medicationNutritional Support Program
Specialized nutritional intervention addressing chemotherapy-related side effects, maintaining lean body mass, and supporting immune function through personalized meal planning and supplementation.
dietaryMolecular Response Surveillance
Regular PCR testing for RUNX1-RUNX1T1 transcript levels to assess treatment response and detect early relapse. Rising levels may trigger preemptive intervention strategies.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia T 8 21 Q22 Q22 1 Cn372149?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2024 ELN recommendations. Blood. 2024;143(5):424-447.
Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2022;40(8):825-836.
Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2022;139(15):2315-2330.
Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2020;116(3):354-365.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia T 8 21 Q22 Q22 1 Cn372149. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy